---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-156202"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:55:29.649851+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics shareholders approve reverse stock split and elect three directors

## Summary
- Approved 1-for-10 reverse stock split with 31,461,878 votes for, 1,019,669 against, 78,724 abstentions.
- Elected Class II directors Dirk Thye, David Lamond, and Luca Benatti to serve until 2027 annual meeting.
- Ratified BDO USA as independent registered accounting firm for fiscal year ending Dec 31, 2024.
- Advisory say-on-pay approved: 17,945,554 for, 429,833 against, 94,767 abstentions (14,090,117 broker non-votes).

## SEC filing metadata
- accession: 0001193125-24-156202
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312524156202/0001193125-24-156202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312524156202/d844037d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-156202
- JSON: https://secwatch.observer/filing/0001193125-24-156202.json
- Plain text: https://secwatch.observer/filing/0001193125-24-156202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.